JonesTrading Maintains Buy Rating and $82 Price Target for Rapport Therapeutics
JonesTrading analyst Justin Walsh has reaffirmed a 'Buy' rating and a $82 price target for Rapport Therapeutics, Inc. (NASDAQ: RAPP).
Stocks · News reference
Filed: 2026-11-04 AccNo: 0001193125-26-446202 Size: 394 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
JonesTrading analyst Justin Walsh has reaffirmed a 'Buy' rating and a $82 price target for Rapport Therapeutics, Inc. (NASDAQ: RAPP).
Following the company's third-quarter earnings report, several financial institutions, including UBS and Guggenheim, adjusted their price targets for Rapport Therapeutics.
Rapport Therapeutics announced its financial results for the third quarter of 2026, reporting a net loss of $40.2 million and providing updates on its clinical pipeline, including the RAP-219 program.
Rapport Therapeutics announced that its management team will participate in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in November 2026.